Dianthus Therapeutics (DNTH) P/S ratio

P/S ratio today
1649.8×

Dianthus Therapeutics (DNTH) trades at 1649.8× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 116.5×. That is 514.1% higher than the 19.0× of fiscal 2023. Figures as of 18 Nov 2026, 03:11 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
1649.8×
P/S ratio, fiscal 2024
116.5×
Change on fiscal 2023
+514.1%
Highest on record
116.5×fiscal 2024
Lowest on record
14.8×fiscal 2022
Fiscal years on record
32022–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Dianthus Therapeutics P/S ratio, in more detail

Today's figure is 1316.4% above the fiscal 2024 year-end.

Across the 3 fiscal year-ends on record (2022–2024), the highest was 116.5× in fiscal 2024 and the lowest 14.8× in fiscal 2022. Today's P/S ratio is above every one of the 3 fiscal year-ends on record; their median is 19.0×.

History · 3 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Dianthus Therapeutics P/S ratio, year by year

Dianthus Therapeutics (DNTH) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today1649.8×—$86.98—
2025——$41.21$0.05
2024116.5× 514.1% up$21.80$0.19
202319.0× 28.3% up$10.40$0.55
202214.8×—$6.40$0.43
2021——$70.88—
2020——$125.44—
2019——$242.56—
2018——$91.20—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on DNTH

Dianthus Therapeutics, figure by figure

Dianthus Therapeutics (DNTH) overview: price, valuation and scorecardAll health care companies by market value

Dianthus Therapeutics P/S ratio: questions and answers

What is Dianthus Therapeutics's P/S ratio?

Dianthus Therapeutics (DNTH) trades at 1649.8× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 116.5×. That is 514.1% higher than the 19.0× of fiscal 2023.

Is Dianthus Therapeutics's P/S ratio high or low compared with its own history?

Today's P/S ratio is above every one of the 3 fiscal year-ends on record; their median is 19.0×.

What are the highest and lowest P/S ratio figures on record for Dianthus Therapeutics?

Across the 3 fiscal year-ends on record (2022–2024), the highest was 116.5× in fiscal 2024 and the lowest 14.8× in fiscal 2022.

How is Dianthus Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Dianthus Therapeutics (DNTH) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/DNTH/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.